VICTORIA, BC, Jan. 23, 2017 /CNW/ - Emerald Health
Therapeutics Inc. (TSXV: EMH) ("Emerald" or the
"Company") is pleased to announce that management will
present at Canaccord Genuity's inaugural Cannabis
Investor Day on Thursday, January 26,
2017 at 3:10 p.m. Pacific
Time. The conference will be taking place at the
Fairmont Waterfront Hotel in Vancouver,
BC.
"We believe cannabinoid medicines present an unparalleled
opportunity for use as adjuvants (supplements) or replacements to a
host of conventional pharmaceutical medicines that are typically
much more toxic and potentially less efficacious. As an example, a
therapeutic alternative to opiates. It's with that in mind that we
remain focused on developing high quality cannabis-based medicines,
backed by clinical efficacy, with standard dosing and conventional
delivery mechanisms. We look forward to sharing this vision
and participating in Canaccord Genuity's
event," says Avtar Dhillon,
M.D., Executive Chairman of Emerald.
For additional information on the event, please contact
your Canaccord Genuity representative.
Join us on our journey of making lives better through
cannabis science.
For more information, explore our website and investor
presentation here (www.emerald.care/about)
ON BEHALF OF THE BOARD
Jim Heppell
Lead Director
Emerald Health Therapeutics Inc.
Emerald Health
Therapeutics is a Licensed Producer under ACMPR, capable of
cultivating and selling both dried medical cannabis flower and
medical cannabis oils in Canada.
Emerald operates out of a GMP-compliant indoor facility in
Victoria, British Columbia, with
plans for a 32 acre purpose built hybrid greenhouse expansion in
metro Vancouver. Emerald prides
itself on being one of Canada's
most medically focused producers with amongst the most
pharmaceutically qualified management teams in the industry. We aim
to capture unique corners of both the medical and future
recreational cannabis market through proprietary strains,
defensible intellectual property, and superb patient and consumer
experience.
SOURCE Emerald Health Therapeutics, Inc.